CTOs on the Move

Keros Therapeutics

www.kerostx.com

 
Keros Therapeutics is dedicated to the discovery and development of novel therapeutics for neuromuscular diseases
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.kerostx.com
  • 99 Hayden Avenue
    Lexington, MA USA 02421
  • Phone: 617.314.6297

Executives

Name Title Contact Details

Funding

Keros Therapeutics raised $23M on 01/08/2019
Keros Therapeutics raised $56M on 03/04/2020

Similar Companies

Two Pore

Two Pore Guys has created a digital, hand-held, single molecule biosensor that rivals the sensitivity of expensive medical lab equipment, yet is as inexpensive and easy to use as a blood glucose monitor.

Synchem

Synchem, Inc. is a Elk Grove Village, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kansas Bioscience Organization

Kansas Bioscience Organization is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intact Vascular

Founded in 2011, Intact Vascular located in Wayne, PA is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack Endovascular System™ is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheral artery disease. Intact Vascular is committed to developing safe, efficacious and easy to use products for patients with vascular disease and for the physicians who treat them.

Keryx

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a team of approximately 200 committed people working with passion to identify meaningful new medicines to advance the care of people with kidney disease. We have assembled a deep concentration of kidney care experts, including nephrologists, renal dietitians, nurses and industry veterans in nephrology. Together, we strive to raise awareness of the kidney disease epidemic, give voice to this underserved population, and help healthcare professionals to improve the care of their patients. In September 2014, the U.S. Food and Drug Administration approved Keryx`s first medicine, Auryxia® (ferric citrate) tablets. Keryx established its corporate headquarters in Boston`s innovation district to support the U.S. launch of Auryxia. Patients have been and continue to be at the center of our nearly 20 year corporate history.